Lilly Diabetes Extends Feelers Into Other Diseases
Eli Lilly leads the way in diabetes and is using its current portfolio to find advantageous opportunities in related therapeutic areas.
You may also be interested in...
Amgen and Sanofi/Regeneron will pay deeper discounts if patients taking Repatha and Praluent don’t experience similar levels of LDL-cholesterol lowering as was seen in clinical trials.
Boehringer Ingelheim and Eli Lilly will launch two outcomes trials within the next 12 months investigating their jointly developed diabetes medicine Jardiance (empagliflozin) as a treatment for people with chronic heart failure – enrolling patients both with and without type 2 diabetes.